Mark Boyd
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Boyd is an internationally recognised infectious disease expert. He has led project teams in HIV research in Thailand, as well as at the Kirby Institute for infection and immunity at the University of New South Wales. He has published results from randomised trials that changed international guidelines for the treatment of adults living with HIV worldwide.
Since moving to the University of Adelaide based at the Lyell McEwin Hospital in Adelaide's north, Boyd has shifted his attention to the health needs of people living in the substantially disadvantaged communities that the hospital serves. Transformative improvements in health and wellbeing in these communities will not come from better access to new pharmaceutical magic bullets, but from interventions that decrease the extreme social stress under which many people live - financial instability, housing insecurity, food scarcity, etc. The challenge is to reconfigure the health system to not only provide the standard pharmaceutical and technical solutions, but also work to help solve the social stressors. This guides our research and our passion for meaningful change in healthcare delivery.
Research
My research interests include:
- The Social Determinants of Health: combining an understanding of patients' social context and stressors and intervening as an essential component of healthcare. The goal is the define a healthcare bundle that combines this critical aspect of healthcare with the standard technological and pharmaceutical interventions. This domain is little researched and desperately needs it. This is even more so with the COVID-19 pandemic which will lead to even more disadvantage, particularly in already disadvantaged communities like the City of Playford. There are numerous opportunities in this important area that could provide innovative, fruitful projects from Honours all the way to a PhD. I am very happy to be contacted to discuss and work with students to find something agreeable to all.
- Pathogenesis and Clinical Management of HIV infection: before moving to UofA I spent nearly 20 years doing HIV clinical research. I led an international, multi-centre, randomised controlled trial that changed the guidelines for the management of people living with HIV worldwide. I maintain a presence and reputation in the HIV world and continue to be engaged in national and international research projects in which there is potential for HDR projects based in Adelaide.
- Clinical Trial Design and Implementation: as the Chair of Medicine at the Lyell McEwin Hospital with expertise in clinical trial design I am involved in developing research of all kinds across the full spectrum of medical practice, e.g. hepatology, gastroenterolgy, respiratory, cardiology, etc. I would be more than happy to answer queries about research projects being conducted at the Lyell McEwin Hospital (or Modbury Hospital) to see if we can find something suitable.
-
Expand
-
Appointments
Date Position Institution name 2015 - 2016 Visiting Medical Officer Murrumbidgee Health District 2015 - 2016 Visiting Medical Officer Albury Wodonga Health District 2013 - 2016 Associate Professor University of New South Wales 2007 - 2012 Clinical Project Leader St Vincent's Hospital 2004 - 2007 Senior Consultant in Infectious Diseases and Microbiology Flinders Medical Centre 2000 - 2004 Clinical Project Leader HIV Netherlands Australia Thailand Research Collaboration -
Awards and Achievements
Date Type Title Institution Name Country Amount 2014 Award The Frank Fenner Award for Advanced Research in Infectious Diseases Australasian Society for Infectious Diseases (ASID) Inc. — — 2014 Award Outstanding Reviewer for 2013 — — — 1986 Award The Alfred Houston Senior Prize in Philosophy University of Tasmania — — -
Education
Date Institution name Country Title 2006 Flinders University Australia (MHID) - Master of Health and International Development 2001 - 2006 University of New South Wales Australia MD - Doctor of Medicine 1997 University of Alabama (USA) and Universidad Peruana Cayetano-Heredia (Perú) Peru and United States DCTM&H - Dip. In Clinical. Trop. Med. and Hygiene 1987 - 1992 Flinders University Australia BM, BS Medicine, Surgery 1983 - 1986 University of Tasmania Australia BA Philosophy - English Literature -
Certifications
Date Title Institution name Country 2013 Graduate Certificate in University Learning and Te University of New South Wales Australia 2011 Certificate for Ethics Training for Human Research Monash University Australia 1995 Fellowship Royal Australasian College of Physicians Australia -
Research Interests
-
Expand
-
Journals
Year Citation 2020 Yang, F., Janamnuaysook, R., Boyd, M. A., Phanuphak, N., & Tucker, J. D. (2020). Key populations and power: people-centred social innovation in Asian HIV services.. The lancet. HIV, 7(1), 69-74.
Scopus5 WoS5 Europe PMC22020 Ramachandran, J., Kaambwa, B., Muller, K., Haridy, J., Tse, E., Tilley, E., . . . Wigg, A. J. (2020). Cost effectiveness of treatment models of care for hepatitis C: the South Australian state-wide experience. European Journal of Gastroenterology and Hepatology, 32(10), 1381-1389.
2020 Dickinson, L., Gurjar, R., Stöhr, W., Bonora, S., Owen, A., D'Avolio, A., . . . Moyano, B. (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: A sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 75(3), 628-639.
Scopus22020 Vannakit, R., Andreeva, V., Mills, S., Cassell, M., Jones, M., Murphy, E., . . . Phanuphak, N. (2020). Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations. The Lancet HIV, 7(5), e366-e372.
Scopus3 WoS32020 Lau, A., Kong, F., Fairley, C., Templeton, D., Amin, J., Boyd, M., . . . Hocking, J. (2020). Factors associated with early resumption of condomless anal sex among men who have sex with men after rectal chlamydia treatment. Sexually Transmitted Diseases, 47(6), 389-394.
2020 Mwasakifwa, G., Amin, J., White, C., Center, J., Kelleher, A., & Boyd, M. (2020). Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.. HIV Medicine, 21(8), 492-504.
2020 Thomson, S., Doan, T., Liu, D., Schubert, K. O., Toh, J., Boyd, M. A., & Galletly, C. (2020). Supporting the vulnerable: developing a strategic community mental health response to the COVID-19 pandemic. Australasian Psychiatry, 28(5), 492-499.
2020 Denholm, J., Davis, J., Paterson, D., Roberts, J., Morpeth, S., Snelling, T., . . . Morpeth, S. (2020). The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial. Trials, 21(1), 646.
Scopus12020 Vannakit, R., Andreeva, V., Mills, S., Cassell, M., Jones, M., Murphy, E., . . . Phanuphak, N. (2020). HIV programmes in countries within the Asia-Pacific region – Authors' reply. The Lancet HIV, 7(8), e530-e531.
2020 Chakraborty, A., Pearson, O., Schwartzkopff, K. M., O'rourke, I., Ranasinghe, I., Mann Mah, P., . . . Wittert, G. (2020). The effectiveness of in-hospital interventions on reducing hospital length of stay and readmission of patients with Type 2 Diabetes Mellitus: a systematic review.. Diabetes research and clinical practice, 108363.
2019 Bell, S., Mena, G., Dean, J., Watts, P., Howard, C., Boyd, M., . . . Gartner, C. (2019). Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 31(4), 436-442.
2019 Boyd, M., Boffito, M., Castagna, A., & Estrada, V. (2019). Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Medicine, 20, 3-11.
Scopus5 WoS4 Europe PMC12019 McManus, H., Callander, D., Donovan, B., Russell, D., O'Connor, C., Davies, S., . . . Guy, R. (2019). Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015. Medical Journal of Australia, 210(6), 269-275.
Scopus3 WoS2 Europe PMC12019 Melaku, Y., Gill, T., Appleton, S., Hill, C., Boyd, M., & Adams, R. (2019). Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: An 18-year follow-up of the North West Adelaide Health Study. BMJ Open, 9(8), e030079.
2018 Giles, M. L., Gartner, C., & Boyd, M. A. (2018). Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?. AIDS Research and Therapy, 15(1), 5 pages.
Scopus3 WoS3 Europe PMC22018 Wright, E., Grulich, A., Roy, K., Boyd, M., Cornelisse, V., Russell, D., . . . Zablotska, I. (2018). Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.. Journal of Virus Eradication, 4(2), 143-159.
Europe PMC22018 Mwasakifwa, G., Moore, C., Carey, D., Amin, J., Penteado, P., Losso, M., . . . Boyd, M. (2018). Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy. AIDS, 32(3), 357-361.
WoS1 Europe PMC12018 Haridy, J., Wigg, A., Muller, K., Ramachandran, J., Tilley, E., Waddell, V., . . . Tse, E. (2018). Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience. Journal of Viral Hepatitis, 25(11), 1287-1297.
Scopus12 WoS9 Europe PMC42018 Yao, A., Moore, C., Lim, P., Molina, J. -M., Madero, J., Kerr, S., . . . Boyd, M. (2018). Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial. Antiviral therapy, 23(1), 21-32.
Scopus1 WoS1 Europe PMC12018 Boyd, M., Cooper, D., & Gilks, C. (2018). Towards a universal second-line fixed-dose combination ART. The Lancet HIV, 5(1), e3-e5.
Scopus4 WoS4 Europe PMC32018 Stockdale, A., Saunders, M., Boyd, M., Bonnett, L., Johnston, V., Wandeler, G., . . . Geretti, A. (2018). Effectiveness of protease inhibitor/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of Human Immunodeficiency Virus Type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clinical Infectious Diseases, 66(12), 1846-1857.
Scopus18 WoS18 Europe PMC82018 Boyd, M., & Cooper, D. (2018). Combination ART: are two drugs as good as three?. The Lancet, 391(10123), 817-819.
Scopus2 WoS2 Europe PMC12017 Petoumenos, K., Choi, J., Hoy, J., Kiertiburanakul, S., Ng, O., Boyd, M., . . . Law, M. (2017). CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy. Antiviral Therapy, 22(8), 659-668.
Scopus5 WoS6 Europe PMC22017 Boyd, M., Mocroft, A., Ryom, L., d'Arminio Monforte, A., Sabin, C., El-Sadr, W., . . . Law, M. (2017). Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: a prospective analysis of the D:A:D observational study. PLoS Medicine, 14(11), e1002424-1-e1002424-14.
Scopus7 WoS6 Europe PMC52017 Bell, S., Mena, G., Dean, J., Boyd, M., Gilks, C., & Gartner, C. (2017). Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes. Drug and Alcohol Dependence, 177, 67-70.
Scopus5 WoS5 Europe PMC12017 Boyd, M. (2017). Body composition substudy of the SECOND-LINE study – Author's reply. The Lancet HIV, 4(6), e240.
2017 Bell, S., Dean, J., Gilks, C., Boyd, M., Fitzgerald, L., Mutch, A., . . . Gartner, C. (2017). Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke. International Journal of Environmental Research and Public Health, 14(7), 12 pages.
Scopus4 WoS3 Europe PMC22017 Boyd, M., & Cooper, D. (2017). Long-acting injectable ART: next revolution in HIV?. The Lancet, 390(10101), 1468-1470.
Scopus6 WoS5 Europe PMC32017 Thit, S., Aung, N., Htet, Z., Boyd, M., Saw, H., Anstey, N., . . . Hanson, J. (2017). The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study. BMC Medicine, 15(1), 145-1-145-11.
Scopus8 WoS8 Europe PMC62017 Puhr, R., Petoumenos, K., Youds, D., Law, M., Templeton, D., Ellis, D., . . . Bargh, K. (2017). The impact of changes in HIV management guidelines on time to treatment initiation in Australia. HIV Medicine, 18(9), 701-703.
Scopus3 WoS3 Europe PMC22017 Boyd, M., Amin, J., Mallon, P., Kumarasamy, N., Lombaard, J., Wood, R., . . . Cooper, D. (2017). Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. The Lancet HIV, 4(1), e13-e20.
Scopus5 WoS4 Europe PMC42017 Lau, A., Kong, F., Fairley, C., Donovan, B., Chen, M., Bradshaw, C., . . . Hocking, J. (2017). Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol. BMC Infectious Diseases, 17(1), 35-1-35-9.
Scopus9 WoS10 Europe PMC72017 Aung, N., Hanson, J., Kyi, T., Htet, Z., Cooper, D., Boyd, M., . . . Saw, H. (2017). HIV care in Yangon, Myanmar; successes, challenges and implications for policy. AIDS Research and Therapy, 14(1), 1-7.
Scopus5 WoS5 Europe PMC12017 Rhee, S., Varghese, V., Holmes, S., Van Zyl, G., Steegen, K., Boyd, M., . . . Shafer, R. (2017). Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. EBioMedicine, 18, 225-235.
Scopus18 WoS16 Europe PMC142017 Wright, E., Grulich, A., Roy, K., Boyd, M., Cornelisse, V., Russell, D., . . . Zablotska, I. (2017). Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. JOURNAL OF VIRUS ERADICATION, 3(3), 168-184.
WoS40 Europe PMC142016 Arts, E., & Boyd, M. (2016). Reviewer acknowledgement.. AIDS research and therapy, 13(1).
2016 Zaunders, J., Danta, M., Bailey, M., Mak, G., Marks, K., Seddiki, N., . . . Koelsch, K. (2016). CD4⁺ T follicular helper and IgA⁺ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals. Frontiers in Immunology, 7(OCT), 438.
Scopus6 WoS8 Europe PMC62016 Boyd, M., Cooper, D., Crock, E., Crooks, L., Giles, M., Grulich, A., . . . Yarwood, T. (2016). Sexual transmission of HIV and the law: An Australian medical consensus statement. Medical Journal of Australia, 205(9), 409-412.
Scopus6 WoS7 Europe PMC22016 Winston, A., Stöhr, W., Antinori, A., Arenas-Pinto, A., Llibre, J., Amieva, H., . . . Barea, C. (2016). Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 17(6), 471-478.
Scopus6 WoS4 Europe PMC52016 Lambert-Niclot, S., George, E., Pozniak, A., White, E., Schwimmer, C., Jessen, H., . . . Couffin-Cadiergues, S. (2016). Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 71(4), 1056-1062.
Scopus16 WoS18 Europe PMC142016 Boyd, M., & Cooper, D. (2016). Tenofovir alafenamide: safer, but questions remain. The Lancet HIV, 3(4), e148-e149.
Scopus2 WoS22016 Klassen, K., Kimlin, M., Fairley, C., Emery, S., Anderson, P., & Ebeling, P. (2016). Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporosis International, 27(5), 1737-1745.
Scopus9 WoS7 Europe PMC52016 Klassen, K., Kimlin, M., Fairley, C., Emery, S., Anderson, P., & Ebeling, P. (2016). Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV. Osteoporosis International, 27(5), 1737-1745.
Scopus9 WoS7 Europe PMC52016 Lam, E., Moore, C., Gotuzzo, E., Nwizu, C., Kamarulzaman, A., Chetchotisakd, P., . . . Boyd, M. (2016). Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study. AIDS Research and Human Retroviruses, 32(9), 841-850.
Scopus8 WoS9 Europe PMC62016 Achhra, A., Mwasakifwa, G., Amin, J., & Boyd, M. (2016). Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis. The Lancet HIV, 3(8), e351-e360.
Scopus37 WoS33 Europe PMC222016 Alvarez, E., Belloso, W., Boyd, M., Inkaya, A., Hsieh, E., Kambugu, A., . . . Mallon, P. (2016). Which HIV patients should be screened for osteoporosis: An international perspective. Current Opinion in HIV and AIDS, 11(3), 268-276.
Scopus10 WoS7 Europe PMC82016 Boyd, M., & Cooper, D. (2016). Novel antiretroviral agents and universal access to HIV care. The Lancet HIV, 3(1), e2-e3.
2015 Boyd, M., Moore, C., Molina, J., Wood, R., Madero, J., Wolff, M., . . . Cooper, D. (2015). Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: An exploratory analysis. The Lancet HIV, 2(2), 42-51.
Scopus47 WoS47 Europe PMC362015 Cummins, N., Neuhaus, J., Chu, H., Neaton, J., Wyen, C., Rockstroh, J., . . . Badley, A. (2015). Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine, 2(7), 706-712.
Scopus14 WoS14 Europe PMC82015 Boyd, M., Donovan, B., Prestage, G., Chen, M., Petoumenos, K., Gray, R., . . . Klausner, J. (2015). Is it time to rethink syphilis control?. Clinical Infectious Diseases, 60(2), 325-326.
Scopus4 WoS4 Europe PMC32015 Templeton, D., Wright, S., McManus, H., Lawrence, C., Russell, D., Law, M., . . . Boyd, M. (2015). Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD). BMC Infectious Diseases, 15(1), 1-8.
Scopus3 Europe PMC22015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Erratum: Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 255.
2015 Wright, S., Law, M., Cooper, D., Keen, P., McDonald, A., Middleton, M., . . . Sasisopin, A. (2015). Temporal trends of time to antiretroviral treatment initiation, interruption and modification: Examination of patients diagnosed with advanced HIV in Australia. Journal of the International AIDS Society, 18(1), 19463.
Scopus6 Europe PMC42015 McManus, H., Hoy, J., Woolley, I., Boyd, M., Kelly, M., Mulhall, B., . . . Law, M. (2015). Recent trends in early stage response to combination antiretroviral therapy in Australia. Antiviral Therapy, 20(2), 131-139.
Scopus4 WoS4 Europe PMC32015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 )). PLoS ONE, 10(10), e0140623.
Scopus32015 Boyd, M., & Cooper, D. (2015). The LATTE study: A provocative brew. The Lancet Infectious Diseases, 15(10), 1116-1117.
Scopus1 WoS12015 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. The Lancet Infectious Diseases, 15(7), 793-802.
Scopus76 WoS73 Europe PMC412015 Amin, J., Boyd, M., Kumarasamy, N., Moore, C., Losso, M., Nwizu, C., . . . Cooper, D. (2015). Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection. PLoS ONE, 10(2), e0118228.
Scopus18 WoS18 Europe PMC172015 Han, N., Wright, S., O'Connor, C., Hoy, J., Ponnampalavanar, S., Grotowski, M., . . . Pujari, S. (2015). HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD). HIV Medicine, 16(3), 152-160.
Scopus6 Europe PMC52015 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. G. (2015). Loss to follow-up in the Australian HIV Observational Database. ANTIVIRAL THERAPY, 20(7), 731-741.
WoS12 Europe PMC82015 McManus, H., Petoumenos, K., Brown, K., Baker, D., Russell, D., Read, T., . . . Law, M. G. (2015). Loss to follow-up in the Australian HIV Observational Database. ANTIVIRAL THERAPY, 20(7), 731-741.
WoS12 Europe PMC82015 Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., . . . Arribas, J. R. (2015). Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. LANCET HIV, 2(11), E464-E473.
WoS51 Europe PMC302015 Beyrer, C., Birx, D. L., Bekker, L. -G., Barre-Sinoussi, F., Cahn, P., Dybul, M. R., . . . Montaner, J. S. (2015). The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will. LANCET, 386(9993), 505-507.
WoS16 Europe PMC122014 Raffi, F., Babiker, A. G., Richert, L., Molina, J. -M., George, E. C., Antinori, A., . . . Pozniak, A. (2014). Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. LANCET, 384(9958), 1942-1951.
WoS121 Europe PMC782014 Haskelberg, H., Pocock, N., Amin, J., Ebeling, P., Emery, S., & Carr, A. (2014). Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(4), e94858-1-e94858-8.
WoS4 Europe PMC32014 Haskelberg, H., Cordery, D., Amin, J., Kelleher, A., Cooper, D., & Emery, S. (2014). HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 9(3), e93333-1-e93333-7.
WoS2 Europe PMC22014 McManus, H., Petoumenos, K., Franic, T., Kelly, M., Watson, J., O’Connor, C., . . . Law, M. (2014). Determinants of suicide and accidental or violent death in the Australian HIV Observational Database. PLoS ONE, 9(2), e89089-1-e89089-8.
WoS13 Europe PMC122014 Achhra, A., Boyd, M., Law, M., Matthews, G., Kelleher, A., & Cooper, D. (2014). Moving away from ritonavir, abacavir, tenofovir, and efavirenz (RATE) - Agents that concern prescribers and patients: A feasibility study and call for a trial. PLoS ONE, 9(6), e99530.
Scopus3 WoS3 Europe PMC22014 Amin, J., Becker, S., Belloso, W., Boffito, M., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2014). Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial. The Lancet, 383(9927), 1474-1482.
Scopus116 WoS117 Europe PMC742014 Wright, S., Hoy, J., Mulhall, B., O'connor, C., Petoumenos, K., Read, T., . . . Boyd, M. (2014). Determinants of viremia copy-years in people with HIV/AIDS after initiation of antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 66(1), 55-64.
Scopus16 WoS14 Europe PMC122014 Holt, S., Gracey, D., Levy, M., Mudge, D., Irish, A., Walker, R., . . . Boyd, M. (2014). A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. AIDS Research and Therapy, 11(1), 35-1-35-10.
Scopus10 WoS10 Europe PMC72014 Revell, A., Boyd, M., Wang, D., Emery, S., Gazzard, B., Reiss, P., . . . Larder, B. (2014). A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 15(7), 442-448.
Scopus3 WoS3 Europe PMC12014 Haskelberg, H., Mallon, P., Hoy, J., Amin, J., Moore, C., Phanuphak, P., . . . Emery, S. (2014). Bone mineral density over 96 weeks in adults failing first-line therapy randomised to raltegravir/lopinavir/ritonavir compared to standard second-line therapy. Journal of Acquired Immune Deficiency Syndromes, 67(2), 161-168.
Scopus12 WoS14 Europe PMC122013 Wright, S., Boyd, M., Yunihastuti, E., Law, M., Sirisanthana, T., Hoy, J., . . . Petoumenos, K. (2013). Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region. PLoS ONE, 8(6), e64902-1-e64902-12.
Scopus12 WoS9 Europe PMC122013 Achhra, A., & Boyd, M. (2013). Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature. AIDS Research and Therapy, 10(1), 33.
Scopus22 WoS20 Europe PMC172013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Second-line study team. (2013). HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One, 8(10), e77138-1-e77138-9.
Scopus13 WoS12 Europe PMC92013 Boyd, M., & Cooper, D. (2013). SPRING-2 the future of antiretroviral therapy. The Lancet Infectious Diseases, 13(11), 908-909.
Scopus4 WoS4 Europe PMC32013 Martin, A., Moore, C., Mallon, P., Hoy, J., Emery, S., Belloso, W., . . . Boyd, M. (2013). Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS, 27(15), 2403-2411.
Scopus27 WoS29 Europe PMC202013 Boyd, M., & Donovan, B. (2013). Antiretroviral therapy: Dolutegravir sets SAIL(ING). The Lancet, 382(9893), 664-666.
Scopus3 WoS22013 Schneider, K., Nwizu, C., Kaplan, R., Anderson, J., Wilson, D., Emery, S., . . . Boyd, M. (2013). The potential cost and benefits of raltegravir in simplified second-line therapy among HIV Infected Patients in Nigeria and South Africa. PLoS ONE, 8(2), e54435.
Scopus1 WoS2 Europe PMC22013 Byakwaga, H., Petoumenos, K., Ananworanich, J., Zhang, F., Boyd, M., Sirisanthana, T., . . . Emery, S. (2013). Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: Results from the TREAT Asia HIV Observational Database. Journal of the International Association of Providers of AIDS Care, 12(4), 270-277.
Scopus3 Europe PMC22013 Jansson, J., Wilson, D., Carr, A., Petoumenos, K., & Boyd, M. (2013). Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV. AIDS, 27(8), 1245-1251.
Scopus10 WoS10 Europe PMC102013 Boyd, M. (2013). Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, open-label, non-inferiority study. The Lancet, 381(9883), 2091-2099.
Scopus116 WoS110 Europe PMC842013 Wright, S., Petoumenos, K., Boyd, M., Carr, A., Downing, S., O'Connor, C., . . . Law, M. (2013). Ageing and long-term CD4 cell count trends in HIV-positive patients with 5 years or more combination antiretroviral therapy experience. HIV Medicine, 14(4), 208-216.
Scopus15 WoS13 Europe PMC122013 Petoumenos, K., van Leuwen, M., Vajdic, C., Woolley, I., Chuah, J., Templeton, D., . . . Law, M. (2013). Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD). HIV Medicine, 14(2), 77-84.
WoS22 Europe PMC182013 Guy, R., Wand, H., McManus, H., Vonthanak, S., Woolley, I., Honda, M., . . . Carr, A. (2013). Antiretroviral Treatment Interruption and Loss to Follow-Up in Two HIV Cohorts in Australia and Asia: Implications for 'Test and Treat' Prevention Strategy. AIDS PATIENT CARE AND STDS, 27(12), 681-691.
WoS17 Europe PMC152012 McManus, H., O'Connor, C., Boyd, M., Broom, J., Russell, D., Watson, K., . . . Law, M. (2012). Long-Term Survival in HIV Positive Patients with up to 15 Years of Antiretroviral Therapy. PLoS ONE, 7(11), e48839.
Scopus56 WoS57 Europe PMC452012 Avihingsanon, A., Van Der Lugt, J., Singphore, U., Gorowara, M., Boyd, M., Ananworanich, J., . . . Ruxrungtham, K. (2012). Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: A pilot study. AIDS Research and Human Retroviruses, 28(10), 1170-1176.
Scopus3 WoS22012 Boyd, M., & Mohapi, L. (2012). Stretching delivery of HIV health services. The Lancet, 380(9845), 865-867.
2012 Haskelberg, H., Hoy, J., Amin, J., Ebeling, P., Emery, S., Carr, A., . . . Woolley, I. (2012). Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 7(6), 1-9.
Scopus62 WoS66 Europe PMC482012 Boyd, M. (2012). Dolutegravir-a promising antiretroviral in development. The Lancet Infectious Diseases, 12(2), 90-91.
Scopus7 WoS7 Europe PMC42012 Boyd, M., & Cooper, D. (2012). Optimisation of HIV care and service delivery: Doing more with less. The Lancet, 380(9856), 1860-1866.
Scopus12 WoS12 Europe PMC92012 Carey, D., Pett, S., Bloch, M., Wand, H., MacRae, K., Beileiter, K., . . . Cooper, D. (2012). A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. Journal of Acquired Immune Deficiency Syndromes, 60(2), 143-149.
Scopus17 WoS15 Europe PMC112011 Byakwaga, H., Kelly, M., Purcell, D., French, M., Amin, J., Lewin, S., . . . Emery, S. (2011). Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4 <sup>+</sup> T-cell response: A randomized controlled trial. Journal of Infectious Diseases, 204(10), 1532-1540.
Scopus46 WoS43 Europe PMC372011 Revell, A., Wang, D., Boyd, M., Emery, S., Pozniak, A., De Wolf, F., . . . Larder, B. (2011). The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. AIDS, 25(15), 1855-1863.
Scopus22 WoS19 Europe PMC162011 Martin, A., Amin, J., Emery, S., Baker, D., Carr, A., Cooper, D., & Bloch, M. (2011). Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine. PLoS ONE, 6(10), e26885.
Europe PMC42011 Kowalska, J. D., Friis-Moller, N., Kirk, O., Bannister, W., Mocroft, A., Sabin, C., . . . Lundgren, J. D. (2011). The Coding Causes of Death in HIV (CoDe) Project Initial Results and Evaluation of Methodology. EPIDEMIOLOGY, 22(4), 516-523.
WoS93 Europe PMC742011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
WoS26 Europe PMC212011 Law, M., Woolley, I., Templeton, D., Roth, N., Chuah, J., Mulhall, B., . . . Australian HIV Observational Database (AHOD).. (2011). Trends in detectable viral load by calendar year in the Australian HIV observational database. Journal of the International AIDS Society, 14(1), 10-1-10-7.
WoS26 Europe PMC212011 Wright, S. T., Carr, A., Woolley, I., Giles, M., Hoy, J., Cooper, D. A., & Law, M. G. (2011). CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 58(1), 72-79.
WoS10 Europe PMC72011 Wilson, D., Grulich, A., & Boyd, M. (2011). Overly optimistic forecasts for the impact of treatment of hiv prevention for men who have sex with men. Clinical Infectious Diseases, 53(6), 611-612.
Scopus2 WoS2 Europe PMC12010 Martin, A., Amin, J., Cooper, D. A., Carr, A., Kelleher, A. D., Bloch, M., . . . Emery, S. (2010). Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS, 24(17), 2657-2663.
WoS41 Europe PMC332010 Zhou, J., Li, P., Kumarasamy, N., Boyd, M., Chen, Y., Sirisanthana, T., . . . Pujari, S. (2010). Deferred modification of antiretroviral regimen following documented treatment failure in Asia: Results from the TREAT Asia HIV Observational Database (TAHOD). HIV Medicine, 11(1), 31-39.
Scopus20 WoS19 Europe PMC152010 Carey, D., Amin, J., Boyd, M., Petoumenos, K., & Emery, S. (2010). Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: Systematic review and meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 65(9), 1878-1888.
Scopus32 WoS29 Europe PMC212010 Boyd, M., & Nwizu, C. (2010). Operational research in HIV priority areas: the African way. The Lancet, 376(9734), 4-6.
Scopus1 WoS2 Europe PMC22010 Boyd, M., & Hill, A. (2010). Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. PharmacoEconomics, 28(SUPPL. 1), 17-34.
Scopus12 WoS10 Europe PMC52010 Boyd, M. (2010). Current and future management of treatment failure in low- and middle-income countries. Current Opinion in HIV and AIDS, 5(1), 83-89.
Scopus15 WoS13 Europe PMC122009 Boyd, M. (2009). Improvements in antiretroviral therapy outcomes over calendar time. Current Opinion in HIV and AIDS, 4(3), 194-199.
Scopus42 WoS40 Europe PMC372009 Byakwaga, H., Murray, J., Petoumenos, K., Kelleher, A., Law, M., Boyd, M., . . . Cooper, D. (2009). Evolution of CD4<sup>+</sup> T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression. AIDS Research and Human Retroviruses, 25(6), 569-576.
Scopus4 WoS6 Europe PMC62009 Byakwaga, H., Zhou, J., Petoumenos, K., Law, M., Boyd, M., Emery, S., . . . Mallon, P. (2009). Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy. HIV Medicine, 10(3), 143-151.
Scopus3 WoS3 Europe PMC22009 Boyd, M., Emery, S., & Cooper, D. (2009). Antiretroviral roll-out: the problem of second-line therapy. The Lancet, 374(9685), 185-186.
Scopus17 WoS16 Europe PMC142009 Boyd, M. (2009). Clinical research in low- and middle-income countries.. The virtual mentor : VM, 11(7), 511-515.
2008 Colebunders, R., French, M., Oelrichs, R., & Boyd, M. (2008). Editorial introductions. Current Opinion in HIV and AIDS, 3(4), vii-viii.
2008 Boyd, M., & Pett, S. (2008). HIV fusion inhibitors: A review. Australian Prescriber, 31(3), 66-69.
Scopus12008 Boyd, M., & Byakwaga, H. (2008). Considering the benefits of disease-specific interventions on overall public health. The Lancet Infectious Diseases, 8(5), 278.
Scopus1 WoS1 Europe PMC12008 Oelrichs, R., & Boyd, M. (2008). Evidence and policy in the globalized response to AIDS. Current Opinion in HIV and AIDS, 3(4), 477-480.
2008 Boyd, M., Truman, M., Hales, G., Anderson, J., Dwyer, D., & Carr, A. (2008). A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study). Antiviral Therapy, 13(3), 449-453.
Scopus8 WoS7 Europe PMC52007 Boyd, M., & Cooper, D. (2007). Second-line combination antiretroviral therapy in resource-limited settings: Facing the challenges through clinical research. AIDS, 21(SUPPL. 4), S55-S63.
Scopus31 WoS27 Europe PMC262007 Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., & Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54.
Scopus14 WoS11 Europe PMC112007 Boyd, M., Menon, P., Graves, S., & Gordon, D. (2007). A febrile illness with generalized papular rash involving the palms and soles. Clinical Infectious Diseases, 44(5), 704-756.
2007 Snelling, T., Ossowicz, C., & Boyd, M. (2007). Case report: Co-infections in an HIV-infected man from Malawi. American Journal of Tropical Medicine and Hygiene, 76(1), 180-181.
2007 Autar, R., Boyd, M., Wit, F., Ruxrungtham, K., Sankote, J., Lange, J., . . . Reiss, P. (2007). Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. Antiviral Therapy, 12(8), 1265-1271.
Scopus5 WoS7 Europe PMC52007 Cooper, D., Cahn, P., Lewin, S., Kaldor, J., McClure, C., Kort, R., & Boyd, M. (2007). The Sydney Declaration: a call to scale up research. Lancet, 370(9581), 7-8.
Scopus14 Europe PMC102007 Boyd, M. (2007). Indinavir: The forgotten HIV-protease inhibitor. Does it still have a role?. Expert Opinion on Pharmacotherapy, 8(7), 957-964.
Scopus14 WoS14 Europe PMC92007 Kerr, S., Duncombe, C., Avihingsanon, A., Ananworanich, J., Boyd, M., Sopa, B., . . . Ruxrungtham, K. (2007). Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. Journal of the International Association of Physicians in AIDS Care, 6(1), 36-46.
Scopus9 Europe PMC62007 Boyd, M., & Hedger, S. (2007). An unusual cause of severe metabolic acidosis [5]. Medical Journal of Australia, 186(3), 158.
2006 Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., . . . Reiss, P. (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. Journal of Infectious Diseases, 194(5), 642-650.
Scopus24 WoS26 Europe PMC192006 Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek, M., . . . Miners, J. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenetics and Genomics, 16(5), 321-329.
Scopus48 WoS39 Europe PMC282006 Boyd, M., Siangphoe, U., Ruxrungtham, K., Reiss, P., Mahanontharit, A., Lange, J., . . . Burger, D. (2006). The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. Journal of Antimicrobial Chemotherapy, 57(6), 1161-1167.
Scopus20 WoS19 Europe PMC102006 Boyd, M., Dixit, N., Siangphoe, U., Buss, N., Salgo, M., Lange, J., . . . Ruxrungtham, K. (2006). Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). Journal of Infectious Diseases, 194(9), 1319-1322.
Scopus11 WoS9 Europe PMC62006 Boyd, M., Burger, D., Phanuphak, P., & Cooper, D. (2006). Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis [4]. AIDS, 20(7), 1083-1085.
Scopus3 WoS2 Europe PMC22006 Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., . . . Phanuphak, P. (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: A randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232.
Scopus15 WoS13 Europe PMC102006 Kong, A., Koukourou, A., Boyd, M., & Crowe, G. (2006). Metastatic adenocarcinoma mimicking 'target sign' of cerebral tuberculosis. Journal of Clinical Neuroscience, 13(9), 955-958.
Scopus14 WoS8 Europe PMC72006 Boyd, M., & Rogers, W. (2006). Industry and bioethics: What price the relationship? [3]. PLoS Medicine, 3(6), 0933.
Scopus1 WoS1 Europe PMC12006 Boyd, M., & Reiss, P. (2006). The long-term consequences of antiretroviral therapy: A review. Journal of HIV Therapy, 11(2), 26-35.
Scopus15 Europe PMC122006 Boyd, M., Clezy, K., Lindley, R., & Pearce, R. (2006). Pandemic influenza: Clinical issues. Medical Journal of Australia, 185(10 SUPPL.), S44-S47.
Scopus22 Europe PMC132006 Boyd, M., & Reiss, P. (2006). Erratum: The long-term effects of antiretroviral therapy: A review (Journal of HIV Therapy 11, 2 (28)). Journal of HIV Therapy, 11(3). 2005 Boyd, M., Mootsikapun, P., Burger, D., Chuenyam, T., Ubolyam, S., Mahanontharit, A., . . . Ruxrungtham, K. (2005). Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antiviral Therapy, 10(2), 301-307.
Scopus40 WoS37 Europe PMC282005 Boyd, M., Siangphoe, U., Ruxrungtham, K., Duncombe, C., Stek, M., Lange, J., . . . Phanuphak, P. (2005). Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. HIV Medicine, 6(6), 410-420.
Scopus15 WoS11 Europe PMC62004 Ananworanich, J., Cheunyam, T., Teeratakulpisarn, S., Boyd, M., Ruxrungtham, K., Lange, P., . . . Phanuphak, P. (2004). Creation of a drug fund for post-clinical trial access to antiretrovirals. Lancet, 364(9428), 101-102.
Scopus17 WoS16 Europe PMC102004 Law, W., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., Lange, J., . . . Dore, G. (2004). Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS, 18(8), 1169-1177.
Scopus126 WoS114 Europe PMC892004 Ruxrungtham, K., Boyd, M., Bellibas, S., Zhang, X., Dorr, A., Kolis, S., . . . Patel, I. (2004). Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. Journal of Clinical Pharmacology, 44(7), 793-802.
Scopus25 WoS20 Europe PMC162003 Law, W., Dore, G., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., . . . Cooper, D. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
WoS85 Europe PMC632003 Law, W., Dore, G., Duncombe, C., Mahanontharit, A., Boyd, M., Ruxrungtham, K., . . . Cooper, D. (2003). Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS, 17(15), 2191-2199.
Scopus982003 Boyd, M., Zhang, X., Dorr, A., Ruxrungtham, K., Kolis, S., Nieforth, K., . . . Patel, I. (2003). Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide. Journal of Clinical Pharmacology, 43(12), 1382-1391.
Scopus42 WoS36 Europe PMC262003 Boyd, M., Aarnoutse, R., Ruxrungtham, K., Stek, M., Van Heeswijk, R., Lange, J., . . . Burger, D. (2003). Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. Journal of Acquired Immune Deficiency Syndromes, 34(2), 134-139.
Scopus19 WoS19 Europe PMC142003 Burger, D., Boyd, M., Duncombe, C., Felderhof, M., Mahanontharit, A., Ruxrungtham, K., . . . Reiss, P. (2003). Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. Journal of Antimicrobial Chemotherapy, 51(5), 1231-1238.
Scopus58 WoS51 Europe PMC34 -
Book Chapters
Year Citation 2018 Boyd, M., & Crowe, S. (2018). Indinavir. In M. L. Grayson, S. E. Cosgrove, S. Crowe, W. Hope, J. S. McCarthy, J. Mills, . . . D. L. Paterson (Eds.), Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 4061-4074). Boca Raton, FL; USA: CRC Press.
2010 Boyd, M. A., & Cooper, D. A. (2010). Antiretroviral Therapy. In R. G. Finch, D. Greenwood, S. R. Norrby, & R. J. Whitley (Eds.), Antibiotic and Chemotherapy (9 ed., pp. 427-451). Elsevier Health Sciences. -
Conference Items
Year Citation 2016 Boyd, M. A. (2016). HIV in Myanmar.. Poster session presented at the meeting of 2016 International Congress for Tropical Medicine and Malaria. Brisbane, Queensland, Australia. 2014 Holt, S., Gracey, D., Mudge, D., Irish, A., Sevastos, J., Walker, R., . . . Boyd, M. (2014). RENAL FUNCTION TESTING IN PATIENTS ON TENOFOVIR ANTIVIRAL THERAPY. Poster session presented at the meeting of NEPHROLOGY. WILEY-BLACKWELL.
Grants and Funding
Category 1
| 2014 - 2017 | Clinical Development Award clinical support for 4 years | NHMRC | $404,884 AUD |
| 2013 | Project Grant award support of the SECOND-LINE study | NHMRC | $449,584 AUD |
Category 2
| 2014 | Australian Award Fellowship support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) | Australian Commonwealth Government Department of Foreign Affairs & Trade. | $656,888 |
| 2013 | Australian Award Fellowships support of the combined UNSW/U Sydney Global Intensive Professional Program in HIV (GIPPH) | AusAID | $698,160 |
Category 3
| 2015 | In support of the development of capacity to measure ARV levels in human tissues: | Merck & Co. IISP grant | $20,000 AUD |
| 2015 | Award in support of Faster and smarter identification of at-risk sexually transmitted infection patients via online, mobile and social platforms | auDA foundation | $20,000 AUD |
| 2014 | Award in project support of The association between virological failure and lopinavir plasma drug levels in the SECOND-LINE trial | Gilead Australia Fellowship Research Grants | 2015: $30,000 AUD |
| 2014 | Independent initiative grant support for an analysis of bone turnover, immune activation and inflammatory biomarkers in the SECOND-LINE DXA-substudy, | Grants Merck Global Affairs | 2014: $304,064 AUD |
| 2012 | Award for support of the RATE study | Gilead Australia Fellowship Research Grants | 2013: $20,000 AUD |
| 2012 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2012: $125,000 USD |
| 2012 | Support of the SECOND-LINE study | Merck & Co. | $1,000,000 USD. |
| 2011 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2011: $125,000 USD |
| 2010 | Support of the SECOND-LINE study | The Foundation for AIDS Research | 2010: $125,000 USD |
| 2009 | Support of the SECOND-LINE study | Abbott Inc. | $600,000 AUD |
| 2009 | Support of the SECOND-LINE study | Merck & Co. | 2009: $1,100,000 USD |
| 2008 | Support of the Encore program | Bill and Melinda Gates Foundation | $12,416,901 USD |
-
Expand
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2020 Principal Supervisor Micro Electrode Guided Radiofrequency Ablation-lesion Characteristics and Implications on Long Term Durability of Linear Ablation in an Ovine Model Doctor of Philosophy Doctorate Full Time Ms Tira Rattanakosit -
Other Supervision Activities
Date Role Research Topic Location Program Supervision Type Student Load Student Name 2015 - 2020 Co-Supervisor Biomarkers of Metabolic Outcomes of Second-Line Antiretroviral Therapy Regimens in Low and Middle-Income Countries University of New South Wales Doctor of Philosophy Doctorate Part Time Gwamaka Mwasakifwa
-
Expand
-
Board Memberships
Date Role Board name Institution name Country 2020 - 2019 Co-Chair Asia Pacific AIDS & Coinfections Conference Virology Education Thailand 2015 - ongoing Member Scientific and Program Committee of the Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Conference 2016 Asia Pacific AIDS & Co-infections Asia Pacific AIDS & Co-infections (APAAC) Australia -
Committee Memberships
Date Role Committee Institution Country 2015 - ongoing Chair ASHM International Advisory Group — — 2014 - ongoing Member Australian National HIV Pre-Exposure Prophylaxis (PrEP) Guidance Committee — — 2014 - ongoing Chair RACP Working Group — — 2014 - ongoing President Australasian Society for HIV Medicine (ASHM) — — 2014 - ongoing Chair Gilead ‘HIV and the Body’ educational meeting faculty — — 2013 - ongoing Chair Lyell McEwin Hospital, Discipline of Medicine, School of Medicine University of Adelaide — 2013 - ongoing Member NEAT-id (European Treatment Network for HIV, Hepatitis and Global Infectious Diseases) — — 2013 - ongoing Member Australasian Society for HIV Medicine (ASHM) Clinical Guidance Committee — — 2013 - ongoing Chair National Program Theme B Committee for the ASHM 2013 National Conference — — 2012 - ongoing Member Kirby Institute Higher Degree Committee and Annual Post-Graduate Progress Review academic staff — — 2012 - ongoing Member ASID Prosthetic Joint Infection Trial Steering Committee — — 2012 - ongoing Member ASHM NSW HIV Shared Care Workshop Committee — — 2012 - ongoing Member Australian Society for Infectious Disease (ASID) Native Joint Infection Trial Steering Committee — — 2011 - 2014 Vice-President Australasian Society for HIV Medicine (ASHM) — — 2010 - ongoing Member Australian HIV Observational Database (AHOD) Steering Committee — — 2009 - ongoing Vice-President Australasian Society for HIV Medicine — — 2009 - ongoing Member ASHM Risk Management and Audit Sub-Committee — — 2005 - 2009 Board Member Australasian Society for HIV Medicine — — 2005 - ongoing Board Member Australasian Society for HIV Medicine (ASHM) — — 1999 - 2005 Member Australasian Society for HIV Medicine — — -
Consulting/Advisories
Date Institution Department Organisation Type Country 2014 - ongoing International Advisory Board, Lancet HIV — — — 2014 - ongoing Merck Australian HIV Advisory Board — — — 2013 - ongoing ASHM NSW Expert Advisory Committee — — — 2013 - ongoing Gilead Sciences International HIV Advisory Board — — — -
Editorial Boards
Date Role Editorial Board Name Institution Country 2015 - ongoing Editor-In-chief AIDS Research & Therapy BMC open access journal — — -
Industry Partnerships
Date Engagement Type Partner Name 2014 - 2016 Consultant Honorary Consultant in HIV Medicine, The Albion Centre 2013 - ongoing Consultant HIV and Infectious Diseases Specialist Consultant, Holdsworth House Medical Practice
Connect With Me
External Profiles
